3-[5-(benzo[b]thien-2-yl)-2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5dimethoxyphenyl)-2-propen-1-one | 383174-66-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-[5-(benzo[b]thien-2-yl)-2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5dimethoxyphenyl)-2-propen-1-one
• 英文别名: 3-[5-(Benzo[b]thien-2-yl)2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5-dimethoxy-phenyl)-2-propen 1-one；3-[5-(1-benzothiophen-2-yl)-2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-en-1-one
• CAS: 383174-66-1
• 化学式: C₂₇H₂₄O₆S
• 分子量: 476.55
• InChiKey: UKNSRYQDVWXGQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 四丁基氟化铵 、 四氢呋喃 在 水 、 二氯甲烷 、 Silica gel 、 ethyl acetate n-hexane 作用下， 反应 2.0h， 以Silica gel chromatography (hexane/ethyl acetate, 1:1) gave 0.05 g (46%) of the desired 3-[5-(benzo[b]thien-2-yl)2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5-dimethoxy-phenyl)-2-propen 1-one product as a yellow solid, m.p. 85-105° C.的产率得到3-[5-(benzo[b]thien-2-yl)-2,4-dimethoxyphenyl]-1-(4-hydroxy-3,5dimethoxyphenyl)-2-propen-1-one
  参考文献：
  名称：

  1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders

  摘要：

  已经发现了某些1,3-双(取代苯基)-2-丙烯-1-酮，包括式(I)的化合物可以抑制VCAM-1的表达，因此可用于治疗由VCAM-1介导的患者的疾病。由VCAM-1介导的炎症性疾病的例子包括但不限于关节炎、哮喘、皮炎、囊性纤维化、移植后晚期和慢性实体器官排斥、多发性硬化症、系统性红斑狼疮、炎症性肠病、自身免疫性糖尿病、糖尿病视网膜病变、鼻炎、缺血再灌注损伤、血管成形术后再狭窄、慢性阻塞性肺疾病（COPD）、肾小球肾炎、格雷夫斯病、胃肠道过敏、结膜炎、动脉粥样硬化、冠状动脉疾病、心绞痛和小动脉疾病。

  公开号：

  US07078431B2

文献信息

• 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Meng Q. Charles

  公开号：US20060258735A1

  公开（公告）日：2006-11-16

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括公式（I）化合物抑制VCAM-1的表达，因此可以用于治疗由VCAM-1介导的患者疾病。由VCAM-1介导的炎症性疾病的例子包括但不限于关节炎，哮喘，皮炎，囊性纤维化，移植后晚期和慢性实体器官排斥，多发性硬化症，系统性红斑狼疮，炎症性肠病，自身免疫性糖尿病，糖尿病视网膜病变，鼻炎，缺血再灌注损伤，血管成形术后再狭窄，慢性阻塞性肺疾病（COPD），肾小球肾炎，Graves病，胃肠道过敏，结膜炎，动脉粥样硬化，冠状动脉疾病，心绞痛和小动脉疾病。
• 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Atherogenics, Inc.

  公开号：US06608101B1

  公开（公告）日：2003-08-19

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现了某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括式(I)的化合物能够抑制VCAM-1的表达，并因此可用于治疗由VCAM-1介导的患者疾病。由VCAM-1介导的炎症性疾病的例子包括但不限于关节炎、哮喘、皮炎、囊性纤维化、移植后晚期和慢性实体器官排斥、多发性硬化症、系统性红斑狼疮、炎症性肠病、自身免疫性糖尿病、糖尿病视网膜病变、鼻炎、缺血再灌注损伤、血管成形术后再狭窄、慢性阻塞性肺疾病（COPD）、肾小球肾炎、格雷夫斯病、胃肠道过敏、结膜炎、动脉粥样硬化、冠状动脉疾病、心绞痛和小动脉病。
• Protection against oxidative stress and inflammation by a cytoprotective response element
  申请人：——

  公开号：US20040023233A1

  公开（公告）日：2004-02-05

  This invention is in the area of regulatory DNA sequences and their methods of use. Specifically, DNA sequences found in the regulatory region of cytoprotective genes are described that are termed cytoprotective response elements. DNA constructs also are provided that include cytoprotective response elements operably linked to heterologous protein coding sequence, as well as cells and non-human organisms that include the cytoprotective response elements optionally operably linked to a heterologous protein coding sequence, and a method for screening for a compound that increases mRNA or protein regulated by a cytoprotective response element. It has been discovered that the cytoprotective response elements mediate the coordinate activation of certain genes that protect cells from damaging effects of oxidative stress, and that they do so, for example during conditions of hemodynamic shear stress.

  本发明涉及调节性DNA序列及其使用方法。具体地，描述了在细胞保护基因的调节区域中发现的DNA序列，称为细胞保护响应元素。还提供了包括细胞保护响应元素与异源蛋白编码序列可操作链接的DNA构建物，以及包括细胞保护响应元素（可选择性地与异源蛋白编码序列可操作链接）的细胞和非人类生物，以及一种筛选增加由细胞保护响应元素调节的mRNA或蛋白质的化合物的方法。发现细胞保护响应元素介导了某些基因的协同激活，这些基因保护细胞免受氧化应激的损害，例如在血流动力剪切的条件下。
• 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS
  申请人：Atherogenics, Inc.

  公开号：EP1330448A2

  公开（公告）日：2003-07-30
• US6608101B1
  申请人：——

  公开号：US6608101B1

  公开（公告）日：2003-08-19